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ABSTRACT
Various signaling pathways exert critical roles in the epithelial to mesenchymal 
transition (EMT) and cancer stem cells (CSCs). The Wnt/beta-catenin, PI3K/PTEN/
Akt/mTORC, Ras/Raf/MEK/ERK, hedgehog (Hh), Notch and TP53 pathways elicit 
essential regulatory influences on cancer initiation, EMT and progression. A common 
kinase involved in all these pathways is moon-lighting kinase glycogen synthase 
kinase-3 (GSK-3). These pathways are also regulated by micro-RNAs (miRs). TP53 
and components of these pathways can regulate the expression of miRs. Targeting 
members of these pathways may improve cancer therapy in those malignancies that 
display their abnormal regulation. This review will discuss the interactions of the 
multi-functional GSK-3 enzyme in the Wnt/beta-catenin, PI3K/PTEN/Akt/mTORC, 
Ras/Raf/MEK/ERK, Hh, Notch and TP53 pathways. The regulation of these pathways 
by miRs and their effects on CSC generation, EMT, invasion and metastasis will be 
discussed.
INTRODUCTION
Glycogen synthase kinase-3 (GSK-3) is moon-
lighting kinase which phosphorylates multiple proteins on 
serine (S) and threonine (T) residues. GSK-3 activity is 
regulated by many kinases and phosphatases including: 
the Akt, ERK, FYN, p38MAPK, PKA, PYK2 and Src, the 
protein phosphatases PP1 and PP2A. Phosphorylation of 
GSK-3 by many of these kinases results in inactivation of 
GSK-3 activity, while dephosphorylation of GSK-3 by the 
protein phosphatases often result in activation of GSK-3 
activity [1-3]. Figure 1 presents a diagram of the kinases 
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and phosphatases that regulate GSK-3 activity. Also 
presented in this figure in the bottom portion are some of 
the different types of substrates phosphorylated by GSK-
3. Often when GSK-3 is phosphorylated by some of the 
above mentioned kinases, it is targeted for protoesomal 
degradation. Akt is one of the best described regulators 
of GSK-3. Akt is a component of the PI3K/PTEN/Akt/
mTORC1 pathway. Akt is frequently abnormally activated 
in cancers due to aberrant activity of upstream receptors, 
activating mutations in the catalytic subunit of PI3K 
(p110 alpha, PIK3CA) or inactivating mutations in the 
phosphatase and tensin homolog (PTEN) lipid and protein 
phosphatase. Figure 2 presents an overview of the PI3K/
PTEN/Akt/mTORC1 and Ras/Raf/MEK/ERK pathways 
and how they can interact with GSK-3 and regulate its 
activity. Mutations can occur that result in activation of 
these pathways and others that will influence GSK-3 
activity. The effects of mutations at diverse components 
of these signaling pathways and sensitivity/resistance to 
various therapeutics have been recently summarized [4-9]. 
GSK-3 has many downstream substrates besides 
glycogen synthase kinase. That is why it is sometimes 
referred to as a moon-lighting kinase. Some of these 
proteins play important roles in CSC generation/
propagation, invasion and metastasis. Mutations which 
result in abnormal GSK-3 activity can have effects on 
the Wnt/beta-catenin pathway and alter the regulation of 
EMT, and cancer development and metastasis. Figure 3 
presents a diagram of some of the types of proteins that 
GSK-3 interacts with and regulates that are important in 
EMT. GSK-3 can also interact with and regulate other 
important developmental pathways implicated in cancer 
Figure 1: Regulation of GSK-3 Activity by Kinases and Phosphatases and Types of Substrates of GSK-3. On top side of 
figure above GSK-3 are various kinases which regulate GSK-3. They are depicted in green ovals. Phosphatases which activate GSK-3 are 
shown in yellow octagons. Amino acid phosphorylation sites which when phosphorylated result in inactivation of GSK are indicated in 
yellow hemispheres with red letters. The Y216 phosphorylation site which results in activation of GSK-3 is presented in a yellow hemisphere 
with green letters. Phosphorylation/dephosphorylation events which result in activation of GSK-3 activity are indicated as green arrows. 
Phosphorylation events which result in inactivation of GSK-3 activity are indicated with red arrows with closed end. On bottom side of the 
figure below GSK-3 are examples of some of the proteins phosphorylated by GSK-3. Phosphorylation events that result in inactivation are 
indicated by yellow circles with a red Ps inside. Phosphorylation events that result in activation are indicated by yellow circles with green 
Ps inside. Types of proteins phosphorylated by GSK-3 include: proteins involved in Wnt/beta-catenin signaling, (e.g., APC, Axin, and 
LRP6) in red ovals as they are activated by GSK-3 phosphorylation or beta-catenin indicated in a grey oval as it is inactivation by GSK-3 
phosphorylation. Anti-apoptotic models such as Mcl-1, kinases such as FAK and mTORC components such as Rictor which are inactivated 
by GSK-3 phosphorylation are indicated in grey ovals. Transcription factors which are activated by GSK-3 phosphorylation are indicated 
by yellow diamonds. Transcription factors which are inactivated by GSK-3 phosphorylation are indicated by grey diamonds. This figure is 
presented to provide the reader an idea of the multiple kinases and phosphatases which can regulate GSK-3 on multiple phosphorylation 
residues and substrates which can be phosphorylated and either inactivated or activated by GSK-3 phosphorylation. 
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Figure 2: Regulation of GSK-3 Activity by Growth Factor Signaling. Two pathways activated by growth factors include 
the PI3K/PTEN/Akt/mTORC1 and Ras/Raf/MEK/ERK signaling pathways. Some of the regulatory interactions between GSK-3 and 
PI3K/PTEN/Akt/mTOR and Ras/Raf/MEK/ERK pathways are indicated. A generic growth factor (GF) is indicated in purple and the 
corresponding growth factor receptor (GFR) are indicated in green and yellow. Ras is indicated by a purple oval. Shc, Grb2 and SOS are 
indicated in orange ovals. Kinases are indicated in green ovals. The p85 regulatory and the p110 catalytic subunits of PI3K are indicated in 
green ovals. The PTEN phosphatase which dephosphorylates phosphatidylinositol (3,4,5)-trisphosphate (PIP3) into phosphatidylinositol 
(4,5)-bisphosphate (PIP2) (yellow ovals) is indicated in a light brown octagon. The PP2A and PP1 phosphatases which may activate GSK-
3 by dephosphorylation are indicated in yellow octagons. TSC1 and TSC2 are indicated in light brown semi-circles. mTOR interacting 
proteins which positively regulate mTOR activity are indicated in yellow ovals. mTOR interacting proteins which negatively regulate 
mTOR activity are indicated in light brown ovals. Transcription factors activated by either ERK or Akt phosphorylation are indicated in 
yellow diamonds. The Foxo transcription factor FKHR that is inactivated by Akt phosphorylation is indicated by a light brown diamond. 
beta-catenin is indicated in light brown oval as it is inactivated after GSK-3 phosphorylation. Some of the types of proteins which are 
regulated by the beta-catenin pathway are indicated (c-Myc, c-Jun, PPPARδ, DKK, Axin2, VEGF, cyclin D). They are colored in light 
brown as their expression is inhibited by GSK-3 phosphorylation of beta-catenin. In addition, KRas can induce ERK which can result 
in activation of Ets and GSK-3 expression which can in turn have effects on IkappaK and NF-kappaB activity. Green arrows indicate 
activating events in pathways. Red arrows indicate inactivating events in pathway. Activating phosphorylation events are depicted in yellow 
circles with green Ps inside them. Inactivating phosphorylation events are depicted in yellow circles with red Ps inside them. This figure is 
provided to give the reader an idea of the multiple interactions of GSK-3 with various signaling molecules in the PI3K/PTEN/Akt/mTOR 
and Ras/Raf/MEK/ERK pathways.
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development such as Hh, Gli and Notch. Clearly the 
moon-lightening kinase GSK-3 has many substrates that 
perform diverse functions. Even though we often think of 
signaling pathways as being linear in nature, they are often 
more spider web in design and altering one component 
will tweak many additional pathways. 
GSK-3 AND CSCS
The transcription factor Snail is involved in the 
regulation of gene transcription and is often activated 
in EMT and metastasis. Snail is important in regulating 
the expression of the Nanog transcription factor that is 
important in stemness. The expression and stability of the 
Snail protein is regulated by GSK-3 at multiple levels. 
The Wnt/beta-catenin and PI3K/PTEN/Akt/mTORC1 
signaling pathways will suppress GSK-3 activity. Figure 
4 presents an overview of the effects Wnt/beta-catenin and 
EGFR mediated signaling on GSK-3, on Snail and EMT. 
High levels of Snail have been shown to correlate 
with metastasis in non-small-cell-lung cancer (NSCLC). 
Snail-expressing NSCLC cells have some properties 
present in CSCs. A correlation between Snail expression 
and phosphorylation of Smad1, Akt, and GSK-3beta 
Figure 3: Substrates of GSK-3 which are Involved in EMT. On top of GSK-3 are transcription factors which are inactivated by 
GSK-3 phosphorylation that are indicated in grey diamonds. On bottom of GSK-3 are transcription factors which are activated by GSK-3 
phosphorylation that are indicated in yellow diamonds. Indicated in red ovals are molecules in the Wnt/beta-catenin pathway which are 
activated by GSK-3 phosphorylation which are indicated in red ovals and beta-catenin which is indicated in an orange oval. Also indicated 
in a maroon oval is the Bax pro-apoptotic molecule. The mitochondrial localization of Bax is promoted when it is phosphorylated by GSK-3 
and then it promotes apoptosis. Also indicated are some cell cycle and signaling proteins which are inactivated by GSK-3 phosphorylation 
(PTEN, Cyclin D1 and p21Cip-1) and beta-catenin which are indicated in grey symbols. This figure is presented to provide the reader an 
idea of the various transcription factors, kinases, phosphatases, apoptotic molecules, cell cycle regulator molecules which are regulated by 
GSK-3 phosphorylation and may influence EMT. 
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Figure 4: Overview of Regulation of Snail Activity by GSK-3 and Wnt/beta-catenin and Cytokine Medicated Signaling 
Pathways. In Panel A., Wnt signaling can prevent GSK-3 phosphorylation which results in the absence of Snail phosphorylation which 
can have effects on other transcription factors such as Nanog which can regulate the expression of genes involved in EMT. In Panel B., 
cytokine mediated signaling can result in the activation of multiple signaling pathways including PKC, PI3K/PTEN/Akt and Ras/Raf/
MEK/REK which can result in GSK-3 phosphorylation that inhibits its activity. In the absence of active GSK-3, Snail is not phosphorylated 
can have effects on gene involved in EMT. This figure is presented to provide the reader an idea of some of the mechanisms which can alter 
GSK-3 activity which influence Snail activity and EMT.
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was observed in Snail-overexpressing NSCLC cells. 
The NSCLC CSCs have characteristics of cells that 
have undergone EMT and were shown to have increased 
migration, chemoresistance and sphere forming properties. 
These studies suggest that inactivation of GSK-3beta may 
be involved in NSCLC CSCs [10]. 
ROLES OF WNT/BETA-CATENIN 
PATHWAY AND GSK-3 IN THE 
GENERATION AND MALIGNANT 
PROPERTIES OF CSCS
The earliest description of the involvement of 
the Wnt/beta-catenin pathway and GSK-3 in CSCs was 
probably in leukemia stem cells (LSCs) as they were some 
of the first isolated and characterized CSCs. Certain LSCs 
have been demonstrated to have higher levels of beta-
catenin which also was driving their establishment and 
drug resistance [2, 11-13]. 
Other components of the Wnt/beta-catenin signaling 
pathway may be differentially expressed in certain LSC 
and other types of CSCs, these include loss of proteins 
frequently dysregulated in the Wnt/beta-catenin pathway 
including: functional adenomatous polyposis coli (APC) 
protein, decreased expression of secreted frizzled-
related protein1 (sFRP1), dickkopf-1 (DKK1), increased 
expression of transcription factor 7 like 2 (TCF7L2), 
B-cell CLL/lymphoma 9 (BCL9), frizzled class receptor 
6 (FZD6), wingless-type MMTV integration site family, 
Figure 5: Overview of the Effects of miRs on sFRP Genes and Pathways Involved in EMT. Various miRs can influence the 
expression of key genes involved in EMT. These miRs may display altered regulation in various cancers. In Panel A., are presented the 
effects of miR-1207, that is upregulated in ovarian cancer, on the expression of sFRP1, Axin2 and ICAT mRNAs. These events can result 
in increased Wnt/beta-catenin signaling that leads to cells with the CSC phenotype. These traits are associated with a poor patient survival 
in ovarian cancer patients. In Panel B., the effects of miR-744 on sFRP1, GSK-3beta, and TLE3 mRNAs are presented that in turn leads 
to cells with the CSC phenotype, chemotherapeutic drug resistance and is associated with a poor patient prognosis in pancreatic cancer 
patients. In Panel C., the effects of miR-942 on sFRP4, GSK-3beta, and TLE1 mRNAs are presented that can lead to cells with the CSC 
tumor sphere phenotype and are associated with a poor patient prognosis in esophageal cancer patients. This figure is presented to provide 
the reader an idea of some of the mechanisms in which miRs can regulate the expression of sFRPs that when inhibited can have effects on 
EMT and cancer development. 
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Figure 6: Effects of Sox17 on miR-371-5q Expression and EMT. Upon demethylation of the Sox17 gene promoter region, the 
Sox17 transcription factor is expressed that can induce the transcription of the miR-371-5q miR that can in turn suppress Sox2 and other 
genes involved in EMT, Wnt/beta-catenin signaling and stemness. This figure is presented to provide the reader an idea of some of the 
mechanisms by which the Sox17 transcription factor can regulate miRs expression which can regulate in turn the expression of other Sox 
transcription factors which when inhibited can effects on EMT and cancer development.
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member 5A (Wnt5A), Wnt7. Wnt/beta-catenin signaling 
was determined to be required for self-renewal of not only 
normal hematopoietic stem cells (HSC) but also LSC. 
The Wnt/beta-catenin pathway plays essential 
roles in colorectal cancers (CRC). This pathway also 
plays critical roles in CRC CSC [14-17]. Interactions 
between Wnt and HoxA5 signaling pathways have been 
observed in CRC. Wnt normally suppresses HoxA5 which 
maintains stemness. HoxA5 is a repressor of intestinal 
stem cell fate. A feedback loop between Wnt and HoxA5 
signaling has been observed [18]. When HoxA5 signaling 
becomes active outside the intestinal crypt, Wnt signaling 
is suppressed and differentiation occurs. HoxA5 signaling 
is repressed in CRC. However when HoxA5 signaling 
is induced, loss of the CRC CSC phenotype occurs. 
Importantly, retenoids can induce HoxA5 that can result 
in tumor regression [18]. 
CRC CSCs can be regulated by miRs and large 
intergenic non-coding RNAs (lncRNAs). The lncRNA-p21 
has been determined to be a suppressor of CRC CSCs. 
lncRNA-p21 inhibited beta-catenin expression [19]. 
Hypoxia increases the size, CSC-phenotype, and 
self-renewal properties of CRC CSC cells. This was 
demonstrated to occur by hypoxia-induced Wnt/beta-
catenin signaling and Id2 expression. A Wnt/beta-catenin 
inhibitor could suppress the levels of CSCs observed after 
hypoxia treatment and also suppressed the inhibitor of 
DNA binding 2 (Id2) expression. The Id2 protein inhibits 
the function of basic helix-loop-helix transcription factors 
in a dominant-negative (DN) fashion. Suppression of Id2 
expression also decreased CRC CSC sphere formation. 
These studies document a role between Id2 and Wnt/beta 
catenin expression in CRC CSC formation [20].
Figure 7: Effects of WIF-1 on mIRs and Genes involved in Cancer Progression. Panel A. When the WIF1 promoter region 
is hypermethylated, the WIF1 gene is off. Upon demethylation of the WIF1 promoter region, the WIF1 gene is turned on and there is 
expression of WIF1 mRNA and protein. WIF1 serves to induce the expression of Let-7a and miR-200c that results in decreased expression 
of genes associated with pluripotency and stemness and results in more differentiation and cellular senescence. Panel B. When the WIF1 
gene is on, it can induce miR-200C expression that can in turn effect the expression of genes involved in EMT such as BMI1, ZEB1 and 
ZEB2. This can result in increased E-cadherin signaling, adult stem cell renewal and influence multi-lineage differentiation. This figure is 
presented to provide the reader an idea of some of the mechanisms the WIF1 factor on genes involved in pluripotency, stemness and EMT 
and the roles that miRs may play in these processes. 
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MIRS EFFECTS ON FRIZZLED-
RELATED PROTEINS
Enforced expression of miR-1207 has been shown 
to activate the Wnt/beta catenin in ovarian cancer cells 
with CSC-like properties. This occurred by miR-1207 
targeting and suppressing Frizzled-related protein-1 
(sFRP1), axin-like protein (Axil) or axis inhibition protein 
2 (AXIN2) or conductin, and the inhibitor of beta-catenin 
and TCF-4 (ICAT). All of these proteins are normally 
Figure 8: Effects of TP53 and miR-34 on the Wnt/beta-catenin Pathway. Panel A. GSK-3 can phosphorylate and activate 
TIP60 which is a histone acetyl transferase. Activated TIP60 acetylates TP53 which results in its activation. Activation of TP53 can result 
in transcription of miR-34. miR-34 can suppress many genes in the Wnt/beta-signaling and other signaling pathways. One consequence of 
inhibition of Axin2 is that GSK-3 may be active. Active GSK-3 can phosphorylate Snail which leads to its inactivation. These events can 
lead to decreased Wnt/beta-catenin signaling, EMT, invasion and metastasis. Panel B. Effects of demethylation of the miR-34 promoter 
region by either 5AzaC or SAHA on miR-34 expression and the regulation of gene involved in cell proliferation, self-renewal, invasion, 
EMT, E-cadherin and N-cadherin expression. In addition, miR-34 expression can induce TP53 expression which can influence genes 
involved in cell cycle regulation and apoptosis such as p21Cip-1, p27Kip-1 and Puma. This figure is presented to provide the reader an idea of 
some of the mechanisms that TP53 and miR-34 play on regulation of genes involved in Wnt/beta-catenin signaling and EMT and how the 
TP53 protein may be regulated by GSK-3-induced TIP60 acetylation. Furthermore, the promoter region of the miR-34 gene is regulated by 
methylation that may be altered by 5AzaC or SAHA treatment. 
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suppressors of the Wnt/beta-catenin pathway. Increased 
expression of miR-1207 might also alter GSK-3 activity 
as AXIN2 is suppressed. miR-1207 was determined to 
be upregulated in ovarian cancer cells and specimens. 
miR-1207 expression correlated with poor patient overall 
survival [21]. Figure 5, Panel A, presents a diagram of the 
effects of miR-1207 on the Wnt/beta-catenin pathway.
miR-744 was determined to affect the expression 
of the Wnt/beta-catenin pathway in pancreatic cancer 
and pancreatic spheroid cells. This occurred by miR-
744 targeting SFRP1, GSK-3beta and the transducin-like 
enhancer of Split-3 (TLE3) [22]. miR-744 overexpression 
also increased the tumorigenicity of the pancreatic 
cells. miR-744 is believed to be a novel diagnostic and 
prognostic marker for pancreatic cancer. Overexpression 
of miR-744 resulted in resistance to gemcitabine in vitro 
[23]. Figure 5, Panel B presents a diagram of the effects of 
miR-744 on genes involved in CSC phenotype.
miR-942 has been shown to be upregulated in 
esophageal squamous cell carcinoma (ESCC) and is 
associated with a poor prognosis in ESCC patients. 
Increased expression of miR-942 promoted tumor sphere 
formation. miR-942 was shown to upregulate Wnt/
beta-catenin signaling by targeting sFRP4, GSK-3beta 
and TLE1. These proteins in some cases negatively 
regulate Wnt/beta-catenin signaling. These studies also 
demonstrated that c-Myc binds to the miR-942 promoter 
and stimulates its expression [24]. Figure 5, Panel C 
presents a diagram of the effects of miR-942 on genes 
involved in CSC phenotype.
The BCL-2 inhibitor ABT-263 has been shown to 
synergize with 5-fluorouracil in esophageal cancer. Part 
of the effects was due to the suppression of many genes 
involved with stemness as well as inhibition of the Wnt/
beta-catenin and YAP/SOX9 axes [25]. 
miR-371-5p is downregulated in primary CRC 
tissues compared with matched normal control tissues. 
miR-371-5p suppressed EMT via Wnt-beta catenin 
signaling. miR-371-5p decreased the CRC stemness 
phenotype. Demethylation of the Sox17 gene was shown 
to induce miR-371-5 expression that in turn targeted 
and suppressed Sox2 expression [26]. Figure 6 presents 
a diagram of the effects of miR-371-5p on Sox17 
expression. 
Morphine has been shown to induce Wnt/beta-
catenin expression, EMT and metastasis in breast cancer. 
Nalmefene is an antagonist of morphine and was shown to 
reverse the effects of morphine. Thus treatment of cancer 
patients with the pain killer morphine should be critically 
evaluated [27]. 
The inflammatory process is important in cancer. 
Enteric pathogens have been associated with EMT as 
they may exploit the plasticity of epithelial cells to 
undergo trans-differentiation. This has been associated 
with multiple signaling pathways including Wnt, Notch 
and TGF-beta. In addition, multiple transcription factors 
including: Slug, Snail, Twist, Zeb1 and Zeb2 may suppress 
E-cadherin, and effect EMT. Enteric pathogens may alter 
the EMT pathway and contribute to CSC generation and 
malignant transformation [28]. 
The Wnt inhibitory protein-1 (WIF1) is a member 
of a family of proteins which bind Wnts and inhibit Wnt 
signaling. WIF1 is an extracellular protein which binds 
lipids and prevents Wnt-mediated signal transduction. 
WIF1 has been shown to decrease the quantity of salivary 
gland cancer stem cells and inhibit their anchorage-
independent growth. Decreased expression of WIF1 was 
observed in salivary gland carcinoma ex-pleomorphic 
adenoma (CaExPA). WIF1 downregulation was observed 
to occur by WIF1 promoter hypermethylation and 
loss of heterozygosity (LOH). Re-expression of WIF1 
resulted in a more differentiated phenotype and cellular 
senescence. This reduced the expression of pluripotency 
and stemness markers such as Oct-4 and c-Myc. In 
addition, WIF1 expression decreased Wnt-3A, TCF4, 
c-Kit and Myb expression that are associated with adult 
stem cell self renewal and multi-lineage differentiation 
[29]. The expression of the pri-miR-200c and pri-let7a 
were increased after restoration of WIF1 signaling. These 
miRs are proposed to be negative regulators of stemness 
and cancer progression. WIF1 has been shown to be a 
positive regulator of miR-200c. miR-200c decreased the 
expression of BMI1, ZEB1 and ZEB2 which resulted in an 
increase in E-cadherin expression [29]. Figure 7 presents 
a diagram of the effects of WIF1 and miRs on EMT and 
cancer progression.
INVOLVEMENT OF TP53 AND MIRS 
IN REGULATION OF WNT/BETA-
CATENIN PATHWAY AND EMT AND CSC 
GENERATION
TP53 transactivated miR-34, that in turn suppressed 
the transcriptional activity of TCF/LEF complexes by 
targeting the untranslated regions (UTRs) of genes 
regulated by Wnt/beta-catenin pathway [30, 31]. Loss of 
TP53 function was demonstrated to increase Wnt/beta-
catenin signaling by loss of miR-34 interactions with target 
genes UTRs. miR-34 depletion suppressed TP53-mediated 
Wnt/beta-catenin target gene repression. Loss of p53 or 
miR-34 gene expression was demonstrated to contribute to 
neoplastic progression by triggering the Wnt/beta-catenin 
dependent, invasive activity of CRCs [30]. miR-34 was 
determined to regulate many genes involved in of Wnt/
beta-catenin and EMT genes; namely WNT1, WNT3, 
LRP6 (Low Density Lipoprotein Receptor-Related Protein 
6), AXIN2, CTNNB1 (beta-catenin), LEF1 (Lymphoid 
enhancer-binding factor 1), MET (c-Met, aka hepatocyte 
growth factor receptor), NOTCH1 (Neurogenic locus 
notch homolog protein 1) and SNAI1 (Snail-1) resulting in 
suppression of TCF/LEF transcriptional activity and EMT. 
Oncotarget14231www.impactjournals.com/oncotarget
Loss of functional TP53 activity and miR-34 expression 
has been shown to alter the balance of CSCs and promote 
cancer progression [31]. Figure 8 presents an illustration 
of the effects of TP53 and miR-34 on the Wnt/beta catenin 
pathway, Snail expression and EMT.
miR-504 is a regulator of TP53. miR-504 binds two 
sites in the TP53 3’ untranslated region. Overexpression of 
miR-504 has been shown to suppress TP53 activity [32]. 
Obesity can induce breast tumor progression by increasing 
miR-504 that inhibits TP53. miR-504 has been shown to 
be induced by obesity and regulate TP53 in breast cancer 
[33]. Figure 9 presents a diagram of the effects of TP53, 
miR-34, miR504 on Snail expression and EMT.
miR-504 has also been shown to be important in 
brain cancer. Forkhead box protein P1 (FOXP1) is a target 
of miR-504 in glioma. Suppression of (FOXP1) by miR-
504 resulted in decreased cell proliferation and promoted 
induction of apoptosis. In clinical samples, miR-504 was 
detected at lower levels [34]. 
In contrast, miR-504 was determined to be 
upregulated in nasopharyngeal carcinoma (NPC) radio-
resistant cell lines. On the other hand, the expression of 
nuclear respiratory factor 1 (NRF1) and other proteins 
involved in mitochondrial metabolism was downregulated. 
These studies determined that miR-504 could target and 
decrease NRF1 expression. The expression of other 
proteins involved in mitochondrial respiratory function 
was also downregulated which led to impaired respiratory 
function. The levels of miR-504 were also determined 
in NPC patient sera after radiation and suggested that 
miR-504 may decrease NRF1 and be involved in 
radioresistance in NPC. It was suggested that targeting 
miR-504 might improve the radiation response [35]. 
In contrast, decreased expression of miR-504 was 
associated with a poor prognosis in high-grade glioma. 
The authors suggested that miR-504 levels could serve 
Figure 9: Effects of miR-34 and miR-504 on TP53-Regulated GSK-3 and Snail Expression. Panel A. Effects of TP53 on 
miR-34 expression that can control the expression of Snail and Axin2 expression. When Axin2 is suppressed, GSK-3 can be activated that 
results in suppression of Snail and has negative effects on downstream Nanog and other mRNAs associated with EMT. Panel B. in contrast, 
if miR-504 is expressed, it can suppress TP53 expression the Snail is expressed that has positive effects on EMT. This figure is presented 
to provide the reader an idea of some of the mechanisms that the TP53 protein can regulate Snail, Axin2 and GSK-3 expression which will 
have effects on EMT.
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as an independent prognostic indicator for glioma. 
These studies have indicated that miR-504 may serve a 
tumor suppressor function in glioma. Other studies have 
proposed that miR-504 may serve as an oncogene by 
inhibiting TP53 expression [36]. 
The Trefoil factor 1 protein (TFF1 aka pS2) 
downregulates miR-504 expression, which can serve to 
downregulate TP53 expression. TFF1 is downregulated in 
human gastric cancer patients and genetic elimination in 
mice in results in gastric adenomas and carcinomas. TFF1 
was determined to promote TP53 expression by inhibiting 
miR-504 expression [37]. 
Other studies have shown that miR-504 can 
inhibit the proliferation of hypopharyngeal squamous 
cell carcinoma (HSCC) by targeting CDK6. miR-504 
expression was downregulated in HSCC patient samples 
while CDK6 expression was elevated. In HSCC cell lines, 
expression of miR-504 suppressed CDK6 expression 
while loss of miR-504 enhanced HSCC proliferation [38]. 
MIR-129 REGULATION OF GSK-3 AND 
EMT
miR-129 has been shown to be important in various 
cancers including: breast, endometrial, and hepatocellular 
carcinoma [39-41]. miR-129 can regulate key genes 
involved in EMT such as Snail. Suppression of miR-129-
5p is associated with a poor prognosis in breast cancer 
Figure 10: Effects of GSK-3 on EMT and Drug Resistance. Panel A. miR-451 can suppress c-Myc expression and miR-451 is 
down-regulated in docetaxel-resistant lung adenocarcinoma cells. c-Myc overexpression can induce ERK activation which in turn results in 
GSK-3 phosphorylation and its inactivation. This can result in Snail stabilization which in turn leads to chemoresistance. Panel B. GSK-3 is 
involved in the survival of GMB-CSCs. Suppression of GSK-3 with GSK-3 inhibitors can result in inhibition of PP2A activity, cell growth, 
colony formation and induced programmed cell growth. This figure is presented to provide the reader an idea of some of the mechanisms 
that GSK-3, c-Myc and miR-451 can be involved in cell growth and chemoresistance. 
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[41]. Silencing of miR-129-3b targets Aurora-A and 
promote EMT, invasion and metastasis in HCC [40]. miR-
129 has been shown to regulate GSK-3beta [39]. Thus 
there are critical links between miR-129, GSK-3, EMT 
and other important components in cancer progression 
[39-41].
GSK-3 EFFECTS ON CELL SURFACE 
ADHESION MOLECULES/RECEPTORS, 
EMT, CSCS AND INVASION
The AXL gene encodes a receptor tyrosine kinase 
that when aberrantly expressed is an oncogene. The role 
of Axl in esophageal squamous cell carcinoma (OSCC) 
has been recently investigated. Axl was determined to 
be overexpressed in tumor samples from patients with 
advanced stages of OSCC. Suppression of Axl inhibited 
proliferation, migration and invasion in animal studies. 
Suppression of Axl resulted in inhibition of NF-kappa-B 
induced gene expression and induction of GSK-3beta 
activity. This led to loss of mesenchymal proteins and 
increase in epithelial markers. The PI3K inhibitor 
Wortmannin was determined to inhibit NF-kappaB and 
to activate GSK-3beta signaling and suppressed OSCC 
proliferation. This suppression of OSCC proliferation 
was determined to be dependent on Akl. Thus, the NF-
kappaB and GSK-3 pathways may have opposite roles in 
the development and progression of OSCC [42]. 
The miR-199-3p is involved in osteosarcoma. miR-
199-3p inhibits the migration and invasion of osteosarcoma 
cells. Low levels of miR-199-3p are correlated with 
recurrence and lung metastasis in osteosarcoma patients. 
miR-199-3 is an independent predictor for poor prognosis. 
miR-199-3b was shown to suppress Axl expression and 
inhibit the progression of osteosarcoma. In osteosarcoma 
patient samples, an inverse relationship was observed 
between miR-199-3b and Axl expression [43]. The miR-
34a also suppresses Axl expression in ovarian cancer. 
miR-34a expression was determined to be downregulated 
in ovarian cancer specimens [44]. 
miR-1, miR-133, miR-143 and miR-145 have 
been shown to effect the expression of genes involved in 
various signaling pathways important in cancer, mobility 
and adhesion such as TGF-beta, ErbB3, Wnt and VEGF. 
Ectopic expression of miR-1 or miR-145 suppressed 
viability and colony formation of a gallbladder cancer cell 
line, as well as Axl and VEGF-A expression [45]. Axl has 
also been shown to be involved in acquired resistance to 
gelfitinib and erlotinib in NSCLC. Axl can regulate the 
expression of miR-374a and miR-548b and target Wnt5a 
and cyclin B1 (CCNB1) in gefitinib-resistant lung cancer 
cells. A poor disease-free survival was associated in 
NSCLC patients that had high expression of Axl and miR-
374a [46]. miR-34a and TP53 have been shown to regulate 
Axl expression in B-cell chronic lymphocytic leukemia. 
This tumor-suppressor network has implications for-TP53 
negative patients [47]. 
A head and neck cancer (HNC) cell line (HN5-ER) 
was developed from HN5 cells which displayed an EMT 
phenotype and eroltinib-resistance. The HN5-ER cells 
displayed reduced expression of miR-34a. Upon increased 
miR-34a expression in these cells, Axl expression 
decreased as well as erlotinib-resistance. Upon analysis 
of 302 HNC patient samples, it was determined that high 
Axl expression was associated with poorer survival [48]. 
Inverse Axl and miR-34a expression has also been 
observed in breast cancer cell lines and tumor samples 
[49]. In another study, an inverse expression of miR-34a 
and Axl mRNA expression was observed in breast, CRC 
and NSCLC cell lines. miR-199a/b may also regulate 
Axl expression. However, miR-199a/b expression was 
determined to be suppressed in all the cancer cell lines 
examined in this study. In cells where the miR-34a 
promoter was methylated, there was less expression 
of miR-34a while the miR-199a/b was completely 
methylated in all samples analyzed. In 44 NSCLC tissue 
samples, miR-34a and miR-199a/b were determined to be 
downregulated. Interestingly, longer patient survival was 
correlated with higher levels of miR-34a expression [50].
GSK-3beta has been shown to interact with focal 
adhesion kinase (FAK), Ras-related C3 botulinum toxin 
substrate 1 (Rac1) and c-Jun-N-terminal kinase (JNK) 
in glioblastoma. These interactions are important in 
invasion. Suppression of GSK-3beta was determined to 
inhibit invasion both in vitro and in mouse tumor models 
of invasion. GSK-3beta inhibition suppressed FAK, JNK 
and Rac1 and resulted in decreased lamellipodia and 
invadopodium-like structures. This resulted in changes 
in the localization and activity of Rac1 and F-actin. In 
addition, decreased levels of matrix metallo-proteinases 
were observed. These results point to the potential use of 
GSK-3 beta inhibitors in the treatment of glioblastomas 
[51]. 
The chemokine (C-X-C Motif) Receptor 2/
chemokine (C-X-C Motif) Ligand 5 (CXCR2/CXCL5) 
interaction have been shown to regulate the PI3K/PTEN/
Akt/mTORC1/GSK-3-beta/Snail pathway in HCC. This 
pathway can influence EMT. High levels of CXCR2 were 
associated with poor prognosis in HCC patients. The 
PI3K/PTEN/Akt/mTORC1/GSK-3-beta/Snail pathway 
and EMT phenotype in HCC cells was associated with 
high levels of CXCR2 and CXCL5 expression [52]. 
The twist-related protein 1 (TWIST1) has been 
shown to be involved in oral tongue squamous cell 
carcinoma (OTSSC) invasion. Elevated TWIST1 was 
associated with a poor prognosis in OTSSC patients. 
TWIST overexpression in OTSCC lines was associated 
with phosphorylation of GSK-3beta at S9 [53]. 
A pathway consisting of miR-451, c-Myc, ERK, 
GSK-3beta and Snail has been shown to be important 
in the docetaxel-resistance of lung adenocarcinoma cell 
models (LAD) which have some phenotypes associated 
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with cells having undergone EMT and have increased 
invasive and migratory properties. c-Myc was shown to 
be a target of miR-451. Figure 10, Panel A presents an 
illustration of the effects of miR-451 on c-Myc expression 
and chemoresistance. Overexpression of c-Myc could 
induce the ERK-dependent phosphorylation of GSK-3 
which resulted in its inactivation and induction of Snail. 
miR-451 normally suppresses the EMT phenotype. miR-
451 was down regulated in docetaxel-resistant LAD cells 
[54].
GSK-3beta may be important in regulating the 
survival in GBM cells with CSC-like properties. Inhibiting 
GSK-3 activity suppressed proliferation, colony formation 
and induced programmed cell death. GSK-3beta had 
effects on protein phosphatase 2A (PP2A) and suppression 
of GSK-3beta resulted in decreased levels of PP2A. GSK-
3beta may be important in glioblastoma CSC-like cells 
[55]. Figure 10, Panel B presents an overview of the 
effects of inhibiting GSK-3 in glioma CSCs.
These models presented in Figure 10 document the 
different effects that GSK-3 can have on cell proliferation 
and drug resistance. In Panel A) the effects of miR-451 
on drug resistance and the involvement of c-Myc, GSK-3 
and Snail expression is presented and GSK-3 is associated 
with the survival of GMB-CSCs. In Panel B, suppression 
of GSK-3 is associated with inhibition of cell growth.
Figure 11: Effects of GSK3 on HIF-1alpha, Motility and Metastasis. Panel A. GSK-3 can result in phosphorylation HIF-1alpha 
that results in its inactivation. Suppression GSK-3 can result in HIF-1alpha mRNA stabilization and inhibition of invasion and cell polarity. 
Panel B. Anthocyanins can activate 5’AMP protein kinase (AMPK) that can in turn lead to GSK-3 activation and suppression of beta-
catenin. Panel C. Effects of suppression of PTEN on Akt activation and inhibition of GSK-3 which can lead to PC3 xenograft formation 
upon injection with PTEN-deficient PC3 cells. Src can phosphorylate GSK-3 on Y216 which result in GSK-3 activation. Inhibition of Src or 
GSK-3 with Desatinib or SB415286 respectively, can have effects on PC3 xenograft formation, PC3 motility, cell proliferation and colony 
formation. This can lead to suppression of proliferation and metastasis of HCC cells. This figure is presented to provide the reader an idea 
some of the mechanisms that GSK-3, can be involved in angiogenesis, tumor formation and metastasis.
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Protocadherin 9 (PCDH9) has been determined 
to be either lost or down-regulated in HCC. PCDH9 is 
involved in tumor migration and EMT. PCDH9 has been 
shown to increase the activity of GSK-3beta by inhibiting 
Snail. Thus, PCDH9 could be a novel target to prevent 
metastasis in HCC [56]. 
Epidermal growth factor (EGF) has been shown 
to promote the stability of Snail by suppressing GSK-
3beta activity in prostate cancer. Inhibition of GSK-
3beta results in Snail transcription [57]. In another study, 
Akt has been shown to be important in the regulation of 
GSK-3beta and Snail after basic fibroblast growth factor 
(bFGF) stimulated induction of EMT in prostate cancer 
[58]. Figure 11 presents an overview of some of the 
mechanisms which can alter GSK-3 activity and invasion 
of cancer cells.
GSK-3beta has been shown to be involved in the 
regulation of HIF-1alpha expression Suppression of 
GSK-3beta resulted in increased HIF-1alpha expression 
in osteocarcoma cells by increasing the stability of HIF-1 
alpha mRNA [59]. Figure 11, Panel A, presents a diagrapm 
of the interactions between GSK-3 and HIF-1alpha and 
their importance in events involved in cancer progression.
Cell polarity is important for cell migration. GSK-
3 has been shown to be important in cell polarity. S9-
phosphorylated GSK-3beta was determined to be critical 
for glioma cell invasion. Downregulation of GSK-3alpha 
and GSK-3beta suppressed glioma invasion, while EGF 
was shown to regulate both GSK-3alpha and GSK-3beta. 
It was determined that only GSK-3beta phosphorylated 
at S9 was enriched at the glioma cell’s leading edge in 
migration assays. EGF was determined to upregulate 
GSK-3beta through atypical PKC pathways. In contrast, 
GSK-3alpha was not upregulated in a similar fashion. 
These studies point to the importance of GSK-3beta in 
glioma cell invasion and polarity as well as point to some 
of the different effects of GSK-3alpha and GSK-3beta 
[60]. 
Links between adenosine monophosphate kinase 
(AMPK) and GSK-3 in the regulation of metastasis and 
proliferation have been described in HCC cells exposed 
to anthocyanins obtained from the Korean wild berry 
Meoru. Hep3B cells treated with anthrocyanins suppressed 
beta-catenin activation by GSK-3beta. Figure 11, Panel 
B presents an illustration of the effects of anthocyanins 
on GSK-3 activity and the beta-catenin pathway. The 
dephosphorylation of GSK-3beta (activation) was 
determined to be dependent on AMPK activation [61]. 
The levels of tuberous sclerosis complex 2 (TSC2, 
aka tuberin) and GSK-3beta were examined in clinical 
HCC patient samples as well as precancerious tissues 
and normal livers. GSK-3beta and TSC-2 were detected 
at lower levels than in in normal liver and precancerous 
controls [62]. 
Maelstrom (MAEL) is a novel oncogene located at 
1q24 which is frequently amplified in HCC. MAEL was 
shown to increase Akt activity which resulted in GSK-3 
phosphorylation and Snail stabilization. This led to EMT, 
tumor invasion and metastasis. MAEL was also shown 
to increase the expression of stemness and multidrug 
resistance genes as well as CSC markers at least at the 
mRNA level [63]. 
An Akt-resistant pathway for GSK-3 activation 
has been described in prostate cancer cells. GSK-3beta 
activity has been associated with both tumor promoter and 
tumor suppressor activities. Prostate cancers often display 
elevated levels of Akt. Src may be responsible for GSK-3 
phosphorylation at Y216 which can result in activation of 
GSK-3 even in the presence of activated Akt. Figure 11, 
Panel C, presents an illustration of the importance of GSK-
3 in prostate cancer growth and progression. Suppression 
of GSK-3 by treatment with the GSK-3 inhibitor 
SB415286 suppressed motility, proliferation and colony 
formation in PC3 prostate cancer cells which express large 
amounts of activated Akt due to PTEN deletion. Desatinib 
treatment inhibited proliferation and invasion as well as 
impaired PC3 xenograft formation [64].
The Akt/GSK-3beta pathway is required for TNF-
alpha induced Snail stabilization and EMT in prostate 
cancer PC3 cells. In these studies, TNF-alpha was 
shown to induce NF-kappaB, Akt, ERK and p38MAPK and 
activated Akt and inhibited GSK-3beta activity which 
resulted in elevated Snail activity [65]. The effects of 
TNF-alpha on GSK-3 and Snails activities is depicted in 
Figure 12.
Slug is a zing finger-containing transcriptional 
repressor which is regulated by GSK-3. It suppresses 
E-cadherin expression and stimulates EMT. In NSCLC, 
it was demonstrated that the expression of Slug was 
associated with the levels of S9-phosphorylated GSK-
3beta. GSK-3 can phosphorylate Slug which results in 
protein turnover. Another protein important in regulation 
of Slug is the carboxyl terminus of Hsc70-interacting 
protein (CHIP) which interacts with Slug. Suppression 
of CHIP was shown to stabilize Slug and inhibited its 
ubiquitination and degradation. Increased levels of Slug 
may lead to reduced E-cadherin expression and promote 
migration, invasion and metastasis [66]. 
The enhancer of zeste homolog 2 (EZH2) is 
important in tumor development and progression EZH2 
may also be a substrate for GSK-3. The role of GSK-
3beta and EZH2 has been investigated in nasopharyngeal 
carcinoma (NPC). EZH2 levels were determined to 
correlate with S9-phosphorylated GSK-3beta in NPC 
patient samples. Inhibition of GSK-3beta in NPC cell lines 
lead to upregulation of EZH2. This resulted in increased 
local invasiveness which was shown to be dependent on 
EZH2 [67]. 
The role of the FAT10 oncogene has been 
investigated in HCC. The FAT10 gene is located at 
6q21.3. 6q21.3 is frequently amplified in HCC. FAT10 
is also known as ubiquitin D. It was determined recently 
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Figure 12: Effects of TNF on GSK-3, NF-kappaB and Snail Activities and EMT. TNF can activate multiple signaling pathways 
including: Akt, p38MAPK and ERK that can phosphorylate and inactivate GSK-3 that can promote Snail activity. Snail can prevent the 
expression of the E-cadherin gene and contribute to EMT. TNF can also activate NF-kappaB which can stimulate Snail gene expression 
which also promotes EMT. This figure is presented to provide the reader an idea of some of the mechanisms that TNF-alpha can regulate 
GSK-3, Snail and NF-kappa-activity and EMT.
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that expression of FAT10 correlated with poor prognosis 
and reoccurrence. FAT10 overexpression stimulated 
proliferation and prevented apoptosis. Suppression of 
FAT10 reversed these properties. FAT10 induced EMT and 
invasion. Suppression of Akt inhibited the proliferative 
and anti-apoptotic effects of FAT10 on the HCC cells [68]. 
Fas signaling can induce EMT in gastrointestinal 
(GI) tumors. Fas-ligand (FasL) was shown to suppress 
E-cadherin transcription by increasing Snail expression. 
FasL induced ERK activity which resulted in GSK-3beta 
phosphorylation at S9. Snail then was able to associate 
with beta-catenin in the nucleus which enhanced its 
transcriptional effects. The expression of these proteins 
was examined in human GI cancer specimens. Enhanced 
levels of FasL, Snail, beta-catenin and S9-phosphorylated 
GSK-3beta were detected in GI cancer progression [69]. 
The Klotho protein is a beta-glucuronidase which 
can hydrolyze steroid beta-glucuronides. Klotho is 
important in diabetes and aging. Recently the Klotho 
protein has been proposed to be a tumor suppressor protein 
in many cancer types. Klotho is expressed in renal tubular 
epithelial cells and appears to function as an anti-apoptotic 
protein. The role of Klotho in renal cell carcinoma (RCC) 
has been investigated. Klotho levels were correlated 
negatively with tumor size in 125 RCC patient samples. 
Overall patient survival was correlated with high Klotho 
expression. Klotho appeared to inhibit the PI3K/PTEN/
Akt/GSK-3beta/Snail pathway. Low Klotho levels were 
associated with Snail and activated Akt-1 expression. The 
authors proposed that Klotho suppresses PI3K/PTEN/Akt/
GSK-3/Snail signaling, EMT and invasion. Thus Klotho 
might be a useful therapeutic target in patients with 
advanced RCC [70]. 
TNF-alpha can induce EMT in the CRC line HCT-
116. This results in invasion and metastasis. EMT was 
characterized by increased expression of N-cadherin and 
fibronectin and decreased E-cadherin and Zona occludin-1 
expression. In these CRC cells, increased Snail but not 
Slug, Zeb or Twist expression was detected. Snail was 
shown to be important for EMT in HCT-116 cells. The 
effects of TNF-alpha on Snail activity were determined to 
be mediated by Akt activation and subsequent GSK-3beta 
expression. These studies provide information concerning 
the role of inflammation and CRC metastasis [71]. 
The role of GSK-3beta in invasiveness of pancreatic 
cancer has been investigated. Inhibition of GSK-3beta 
suppressed the proliferation of pancreatic cancer cells and 
sensitized them to gemcitabine and ionizing radiation. 
Decreases in the levels of cyclin D1 expression and Rb 
phosphorylation were observed. Suppression of GSK-
3beta also changed the location of Rac-1 and F-actin and 
altered lamellipodia microarchitecture. Decreased levels 
of MMP2 and FAK phosphorylation were also observed 
[72]. 
The Raf kinase inhibitor protein (RKIP) has been 
shown to bind GSK-3beta and maintain the protein in 
its active configuration. Removal of RKIP stimulates 
activation of p38MAPK which phosphorylates GSK-3beta 
on T390 and inhibits its activity. This relieves the GSK-
3beta- mediated inhibition of cyclin D, beta-catenin and 
Figure 13: Effects of miRs and FZD on Drug Resistance, Invasion and Metastasis. Panel A. The FZD5 gene can influence the 
expression of the MDR1 gene which can result in chemotherapeutic drug resistance. Panel B. GSK-3 can suppress FZD8 which has effects 
on Wnt/beta-catenin signaling, invasion and metastasis. miR-100 can also suppress FZD8 expression which has effects on Wnt/beta-catenin 
signaling, invasion and metastasis. This figure is presented to provide the reader an idea of some of the mechanisms that FZD can regulate 
proteins involved in drug resistance and how they can be regulated by miRs. 
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Slug which promotes EMT. RKIP levels in CRC have 
been shown to correlate with GSK-3beta. The authors 
have suggested that RKIP/GSK-3 maybe be a promising 
therapeutic target [73] 
Galectin-3 (Gal-3) is a member of the beta-
galactoside-binding protein. It may be involved in 
the regulation of pancreatic cell mobility. Silencing 
Gal-3 suppressed cell migration and invasion but not 
proliferation [74]. 
Sirtuin2 (SIRT2) is a NAD-dependent protein 
deacetylase. The sirtuins are involved in a number of key 
biochemical processes including telomere maintenance. 
SIRT2 has been shown to be important in the motility and 
invasiveness of HCC. Suppression of SIRT2 prevented 
EMT phenotypes. SIRT2 was shown to control the 
deacetylation and activity of Akt that in turn regulated 
GSK-3beta/beta-catenin and EMT [75]. 
GSK-3beta can phosphorylate the long form of 
the collapsin response mediator protein-1 (LCRMP-1), 
a protein that is important in migration and invasion. 
LCRMP-1 is associated with a poor clinical outcome 
in non-small cell lung cancer (NSCLC) patients. GSK-
3beta can phosphorylate LCRMP-1 on T268. This 
phosphorylation event is important in the stimulation 
of filopodia, migration and invasion. Patients with low 
GSK-3beta S9 phosphorylation and high LCRMP-1 were 
determined to have a worse overall survival than patients 
with high GSK-3beta S9 and low LCRMP-1 [76]. 
Akt regulates GSK-3beta which in turn controls 
ZEB1 transcription. ZEB1 modifies the expression of 
cytokeratins, vimentin and MMP9. Zeb1 expression was 
shown to be essential for invasion in bladder cancers as 
well as metastasis in vivo [77]. 
Inhibition of GSK-3 suppressed the motility 
of melanoma cells. Inhibition of GSK-3 suppressed 
N-cadherin and Slug expression. GSK-3 inhibitors also 
blocked FAK phosphorylation. These studies describe 
novel roles for GSK-3 in controlling the motility of 
melanoma cells by regulation of N-cadherin and FAK 
expression [78]. 
Figure 14: Effects on TP53 and ∆Np63 on FZD Gene Expression and Wnt/beta-catenin Signaling. Panel A. TP53 can 
induce the CD82 gene that can suppress metastasis. CD82 can also induce expression of miR-203A and inhibit the expression of miR-338-
3p. miR-203A can suppress FZD2 expression which in turn resulted in inhibition Wnt/beta-catenin signaling. Panel B. ∆Np63 can result 
in FZD7 expression that can have effects on Wnt/beta-catenin signaling and is associated with a poor prognosis in TNBC. miR-199A can 
inhibit FZD7 expression which in turn inhibits Wnt/beta-catenin expression. This figure is presented to provide the reader an idea of some 
of the mechanisms that TP53 and ∆Np63 can regulate FZD expression that affects EMT.
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The anti-tumorigenic cytokine TNF-alpha can 
inhibit GSK-3beta activity by stimulating Akt to 
phosphorylate GSK-3beta at S9 in renal carcinoma cells 
(RCC). Treatment of RCC cells with lithium resulted in 
suppression of GSK-3beta and increased levels of MMP9 
and the induction of EMT. Introduction of an activated 
GSK3B gene into RCC cells inhibited TNF-alpha-induced 
anchorage-independent growth as well as tumorigenicity 
in mice. In contrast, introduction of a kinase-deficient 
GSK3B gene into RCC cells promoted EMT, anchorage-
independent growth and tumorigenicity. Thus GSK-3beta 
plays a key role in TNF-alpha induced tumorigenesis of 
RCC [79]. 
Introduction of a kinase-dead (KD) GSK3B 
construct into estrogen receptor positive MCF-7 
breast cancer cells increased their resistance to the 
chemotherapeutic drug doxorubicin and the estrogen 
receptor antagonist 4-hydroxytamoxifen (4HT) [80]. 
Furthermore, introduction of an activated GSK-3beta 
construct increased the sensitivity of the MCF-7 cells to 
doxorubicin and 4HT. The GSK-3beta KD also increased 
the colony formation of the cells in soft agar in the 
presence of doxorubicin. 
Rhubarb can activate GSK-3beta and inhibit HCC 
metastasis by enhancing the degradation and nuclear 
translocation of beta-catenin. Rhubarb also downregulated 
Figure 15: Effects of miRs on Notch Signaling. Panel A. Ectopic expression of miR-34c can result in suppression of Notch4 
expression which blocks self renewal and EMT. Panel B. Overexpression of miR-34a can block Notch1 expression and inhibit mammosphere 
formation, migration, proliferation and drug resistance. Notch1 can serve as a balance between self-renewal and differentiation and is 
regulated by miR-34a. Panel C. Notch1 overexpression can influence EMT and pancreatospheres as well as miRs. These events can 
influence cell growth, clonogenicity and EMT. This figure is presented to provide the reader an idea of some of the mechanisms that Notch 
and miRs can regulate important genes involved in self renewal, differentiation and EMT.
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cyclin D, T-box transcription factor-3 (Tbx3), c-Myc, 
MMP9 and contactin-1. Rhubarb suppressed GSK-3beta 
phosphorylation at S9 and disrupted Wnt signaling [81]. 
Migfilin is a component of focal adhesion 
complexes. Migfilin is thought to be involved in cell-
extracellular matrix adhesion and control of motility in 
ESCCs. Migfilin was shown to be associated negatively 
with metastasis and migfilin inhibited cell motility by 
decreasing the level of free beta-catenin. This occurred in 
part by migfilin promoting the association of GSK-3 and 
beta-catenin [82]. 
Leptin is an important hormone made by adipose 
cells and is important in regulating hunger and diabetes. 
Leptin has been shown to induce Akt to phosphorylate 
GSK-3beta. This results in a decrease in formation of 
the GSK-3beta/LKB1/Axin complex which results in 
upregulation of beta-catenin. Leptin also induces the 
expression of metastasis-associated protein (MTA1) 
which is important in Wnt signaling. Silencing of MTA1 
was shown to prevent leptin-induced Wnt1 expression. In 
leptin-treated breast tumors, a cross-talk between leptin 
and MTA1/Wnt signaling was observed that may be 
important in EMT [83].
EFFECTS OF THE PI3K/PTEN/AKT/
MTORC1/GSK-3 PATHWAY ON INVASION 
AND CSCS
The PI3K/PTEN/Akt/mTORC1 pathway has been 
shown to be important in the invasive and migratory 
properties of certain cancers including ovarian cancer 
[84]. Upregulation of the IGF-1R/mTOR and mevalonate-
isoprenoid biosynthesis (MIB) pathways has been 
observed in colorectal cancer cells with CSC properties. 
Inhibition of IGF-1R/mTOR suppressed CRC CSC growth 
and the expression of CSC markers [85]. 
Greater than 80 proteins associated with protein 
synthesis have been observed to be differentially expressed 
in CSCs prepared from breast CSCs in comparison to their 
adherent breast cancer cells that they were derived from. 
Rapamycin was shown to be very potent in inhibiting 
mammosphere formation. Methionine restriction, which 
mimics caloric restriction, was also determined to inhibit 
CSCs preferentially [86]. 
Combining the antibiotic salinomyin (SAL), which 
may function as a potassium ionophore, with metformin 
was shown to have synergistic effects on the induction 
of cell death in NSCLC CSCs. This occurred in NSCLC 
CSCs regardless of their EGFR, KRas, echinoderm 
microtubule associated protein like 4/anaplastic lymphoma 
receptor tyrosine kinase (EML4/ALK) and serine/
threonine kinase 11/liver kinase B1 (STK11/LKB1) status. 
Higher levels of inhibition of downstream targets of EGFR 
(Akt, ERK1,2) and mTOR (p70S6K) were observed when 
metformin and SAL were combined together than after 
single agent addition [87]. 
WNT PATHWAY ASSOCIATED 
PROTEINS AND CSCS
The B cell-specific Moloney murine leukemia virus 
integration site 1 (BMI1) protein (aka polycomb group 
RING finger protein 4) has been shown to activate the 
Wnt pathway by suppressing the DKK family of Wnt 
inhibitors. The repression of DDK1 by BMI1 resulted in 
increased expression of the Wnt target c-Myc. This in turn 
led to the transcriptional activation of BMI1. These studies 
elucidated a positive feedback BMI1 loop which may be 
important in maintaining the CSC phenotype [88]. 
Another group of proteins which suppresses 
Wnt signaling are the DDK family of Wnt inhibitors. 
Overexpression of certain DKKs in the hematopoietic 
niche can result in suppression of HSC long-term 
repopulating activity [89]. Forced overexpression of 
DKK1 in osteoblasts leads to osteopenia that can disrupt 
the HSC niche as well as the function of HSCs. DKK1 
also plays important roles in inhibiting fracture repair. 
DKK activation in osteoblasts can lead to certain forms 
of osteoporosis. DKK1 has been implicated in the 
progression and metastases of many diseases including 
multiple myeloma (MM), breast cancer, and in those 
prostate cancers where there is bone pathology [90]. 
Osteolytic bone lesions and bone fractures can occur in 
MM patients who express DDK1 [90]. Other cancers 
also expressed decreased levels of DDKs. Lower levels 
of DDK4 were detected in HCC [92]. Certain DKK 
genes were determined to be epigenetically inactivated in 
gastrointestinal and CRC cancers [92]. 
Downregulation of CD133 reduced the metastasis of 
melanoma cells to the spinal cord. The expression of genes 
encoding Wnt inhibitors was observed to be upregulated 
when CD133 (Prominin-1 a cell surface molecule often 
associated with CSCs) was down regulated in melanoma 
cells [93]. 
REGULATION OF FZD PROTEINS BY 
MIRS AND TP53
The FZD proteins play essential roles in Wnt-
mediated signaling pathways. FZD mRNAs are regulated 
by diverse miRs. FZD5 can be involved in the regulation 
of the multidrug resistance gene (MDR1, ABCB1, 
P-glycoprotein) (Figure 13, Panel A). FZD5 can in turn 
be regulated by miR-124 [94]. miR-124 expression can 
block drug resistance (Figure 13, Panel B). GSK-3beta 
expression can block FZD8 expression which is important 
in Wnt/beta-catenin signaling, invasion and metastasis. 
miR-100 can inhibit FZD8 expression that has effect on 
breast cancer invasion and metastasis (Figure 13, Panel 
B) [95]. The miR-199a-5b regulates FZD6 in CRC cells. 
FZD6 is detected at elevated levels in CRC tumor samples 
as compared to adjacent non-cancerous tissue [96]. 
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TP53 can also regulate the cluster of differentiation 
82 (CD82) gene that encodes a membrane glycoprotein. 
CD82 is important in the suppression of metastasis. CD82 
can also modulate miR-203 positively and miR-338-3p 
negatively. miR-203 can inhibit FZD2 mRNA and block 
Wnt/beta-catenin signaling (Figure 14, Panel A) [97].
The TP53 related gene ∆Np63 can regulate the 
expression of FZD7 (Figure 14, Panel B). FZD7 is 
also involved in regulating Wnt/beta-catenin signaling. 
Overexpression of FZD7 is associated with a poor 
prognosis in triple negative breast cancer (TNBC). miR-
199A can suppress FZD8 mRNA which inhibits Wnt/beta-
catenin signaling [98].
WNT SIGNALING IN STEM CELL SELF-
RENEWAL
Stem cells have the capacity to self-renew as well 
as produce specialized cells. The choice to self-renew or 
produce specialized cells may be dictated by extrinsic 
signaling factors which are present in the niche or in an 
area which functions as a signaling center. Many of these 
factors act in the near vicinity of the stem cells in order to 
tightly regulate them. Key pathways involved in regulating 
the niche are: Wnt, bone morphogenic protein (BMP), 
Hh and Notch [99-102]. Altering the activity of the Wnt 
pathway has been shown to affect HSC. Overexpression 
of Axin decreased the number of transplantable HSCs 
[103]. Activation of Wnt signaling by introduction of 
mutant forms of beta-catenin can increase hair follicle 
morphogenesis and hair tumors [104]. Treatment of 
HSC with the Wnt-3a protein increased self-renewal and 
long term reconstitution in irradiated mice [100]. Wnt 
proteins have also been shown to promote maintenance of 
pluripotency in murine ESCs [105, 106]. The mechanisms 
by which Wnt signals maintain stemness are not fully 
elucidated. Clevers and Nusse [99] have suggested that 
stem cells are intrinsically destined to differentiate and 
that Wnt signals could block the differentiation step by 
suppressing differentiation-specific genes as Wnt signals 
can also suppress the expression of certain genes [99].
THE HEDGEHOG (HH) PATHWAY AND 
CSCS
Crocetinic acid can be purified from the commercial 
saffron compound crocetin. Crocetinic acid inhibited 
the expression of both the sonic hedgehog ligand (Shh) 
and smoothened (Smo) in pancreatic CSCs. Smo is a G 
protein-coupled receptor and is a frizzled class receptor. 
Crocetinic acid inhibited the number and size of pancreatic 
CSCs [107]. 
The Hh pathway may be responsible for the 
stemness properties of certain breast cancer cells after 
exposure to chemotherapeutic drugs such as docetaxel. 
Treatment of breast cancer cells with docetaxel resulted 
in release of Shh and increased expression and nuclear 
translocation of Gli-1. These effects appeared to have 
been more prominent in the breast CSCs than in the breast 
cancer cells lacking the CSC properties (aka., the bulk 
cancer). The authors concluded that Hh pathway activation 
by docetaxel did not induce chemosensitivity but instead 
may be required for survival and expansion of the breast 
CSCs after chemotherapy [108]. 
Curcumin may influence CRC CSC. Curcumin may 
effect multiple signaling pathways including Wnt/beta-
catenin, Shh, Notch and PI3K/PTEN/Akt/mTORC. In 
addition, curcumin may have effects on mIRs and EMT 
[109]. 
Mammospheres prepared from the breast cancer 
cell line MCF-7 cells have been shown to be sensitive 
to the bacteria gram positive antibiotic salinomycin, but 
resistant to the chemotherapeutic drug paclitaxel. This 
is in contrast to the parental bulk cancer MCF-7 cells. 
PTCH, SMO, Gli1 and Gli2 were upregulated in the MCF-
7 mammospheres and their expression was sensitive to 
salinomycin but not paclitaxel. Salinomycin inhibited the 
expression of gene targets of the Hh pathway including: 
c-Myc, Bcl-2 and Snail. The expression of SMO and Gli1 
was correlated with the CD44+/CD24- phenotype which 
is often associated with breast CSCs. These characteristics 
were linked with a shorter overall and disease free survival 
of breast cancer patients being treated with chemotherapy 
[110]. 
Gastric CSCs which express CD44(+)/Musashi-1(+) 
were determined to express high levels of Shh and Gli1. 
Suppression of Gli1 activity inhibited the doxorubicin-
resistance of the cells [111]. 
Gli1 has been shown to be a regulator of the Sox2 
transcription factor in NSCLC. Suppression of Hh or Gli1 
inhibited the self-renewal of NSCLC CSC. In addition, 
suppression of EGFR and Hh was shown to reduce the 
viability of NSCLC and the self-renewal of NSCLC CSCs 
[112]. 
The Hh pathway is important in colon carcinoma 
EMT and CSCs [113, 114]. Colon carcinomas are derived 
from the intestinal epithelium. The intestinal epithelium 
undergoes constant renewal by the progeny of stem cells 
which reside in the bottom of the crypts of Lieberkuhn. 
Normal stem renewal is regulated by Wnt/TCF signaling. 
Greater than 90% of colon carcinomas contain inactivating 
mutations in the APC gene or activating mutations in the 
beta-catenin gene (CTNNB1). These mutations result 
in abnormal activity of the TCF family of transcription 
factors which contribute to the genesis of colon 
carcinomas. The abnormal activity of Wnt/TCF has been 
thought to drive the expansion of colon carcinoma CSCs 
and tumor development [115, 116]. 
An intriguing interrelationship between Wnt/TCF 
and Hh/GLI signaling pathways has been documented 
in the metastatic transition of colon carcinomas [113]. 
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Namely, the activity of the Wnt/TCF pathway decreased 
while the activity of the Hh/Gli pathway increased during 
EMT. The Hh/Gli pathway drove the downregulation of 
Wnt/TCF pathway which resulted in the enhancement 
of more primitive embryonic stem cells. Interestingly, 
this group observed that TCF blockade did not suppress 
tumor growth but importantly, it increased Hh/Gli 
signaling. Enhanced Gli1 levels were determined to drive 
the transition of colon carcinomas to a reprogrammed, 
embryonic stem cell-like, metastatic state and the Wnt/
TCF pathway was suppressed. This switch was identified 
in fresh tumor samples from patients. Furthermore, 
increased expression of Wnt pathway inhibitors such as 
DKK1 and sFRP1 in metastatic colon carcinomas and 
liver metastases was observed. The authors suggested 
that the phenotype of advanced and metastatic colon 
carcinomas was only maintained in xenografts. In contrast, 
in in vitro studies with non-metastatic colon carcinomas, 
both the Wnt/TCF and Hh/Gli pathways were expressed 
and necessary. Wnt/TCF activity antagonized tumor and 
metastatic growth and inhibition of Wnt/TCF promoted 
enhanced metastatic growth. Thus, targeting Hh/Gli may 
be more important than suppressing the Wnt/TCF pathway 
in certain cancers.
This group also observed that when colon 
carcinomas with non-metastatic properties and colon 
carcinomas with metastatic properties were cultured in 
vitro, the Wnt/TCF and Hh/Gli pathways interacted at 
multiple levels due to the tissue culture microenvironment. 
Both pathways may regulate c-Myc expression while the 
Wnt/TCF pathway may suppress Gli activity. The authors 
demonstrated that Wnt3/beta-catenin regulated Gli3 
transcription resulting in Gli3 being a repressor of Gli1. In 
contrast, when Hh/Gli1 was enhanced, Gli3 was repressed. 
Beta-catenin can negatively regulate Gli3 and positively 
regulate Gli1 independently of TCF in colon carcinoma 
CD133+ stem cell populations [114]. 
CRC CSC stem cell populations are clearly 
important in CRC carcinogenesis [115, 116]. The effects 
of mutations at multiple oncogenes and tumor suppressor 
genes may be mediated by various signaling pathways.
MIRS AND HH SIGNALING
miR-326 has been shown to target SMO which 
inhibits glioma stemness. SMO was determined to be a 
target of miR-326. Overexpression of miR-326 suppressed 
SMO levels, Hh pathway activity, decreased self-renewal, 
stemness, and induced differentiation of U251 tumor cells. 
Suppression of Hh pathway activity increased miR-326 
activity [117].  
miR-137 has been determined to be down regulated 
in glioma stem cells (GSCs) in comparison to neural 
stem cells (NSCs). The miR-137 promoter region was 
hypermethylated in glioma specimens. miR-137 targets 
RTVP-1 (aka glioma pathogenesis-related protein 1) in 
glioma stem cells and suppresses stemness. The tumor 
suppressor RTVP-1 was determined to be a critical target 
of miR-137. Silencing of RTVP-1 decreased GSC self 
renewal and CXCR4 expression. Overexpression of miR-
137 induced neural differentiation in both NSCs and 
GSCs. Interestingly, expression of pre-miR-137 decreased 
self-renewal and the expression of Oct4, Nanog, Sox2 and 
Shh which are stem cell markers [118]. 
The small molecule Smo inhibitor Erismodegib 
(NPV-LDE-225) has been shown to have effects on 
EMT on regulating miR-21, miR-128 and miR-200 
expression in glioblastoma cells. Erismodegib inhibited 
cell viability and induced apoptosis by suppression 
of miR-21 expression. Erismodegib suppressed the 
expression of pluripotency factors such as c-Myc, Nanog, 
Oct4 and Sox2. Erismodegib had effects on other miRs 
such as induction of miR-128 which suppressed BMI1. 
Erismodegib inhibited EMT by increasing E-cadherin and 
decreasing N-cadherin, Slug, Snail and Zeb1 expression. 
This was postulated to occur via the induction of miR-200 
[119]. 
The Hh pathway is also important in chronic 
myeloid leukemia (CML) LSCs. Suppression of the Hh 
pathway depletes CML LSC. Increased Smo activity was 
associated with reduced miR-326. miR-326 targets Smo 
in CD34+ CML stem/progenitor cells. Overexpression 
of miR-326 downregulated both Smo and proliferation 
in CML CD34+ cells. Thus, miR-326 appears to regulate 
Smo expression in some cell types and may be a 
therapeutic target [120]. 
NOTCH AND CSCS
Prolonged herceptin treatment of NCI-N87 
gastric cancer cells resulted in the recovery of cells that 
were herceptin-resistant. The resistant cells had some 
properties of cells having undergone EMT and were 
more invasive and metastatic. Long term treatment with 
herceptin inhibited phosphorylation of Akt but activated 
Stat-3 which resulted in IL-6 expression. In addition, 
the Notch pathway was activated in the resistant cells, 
as upregulation of the Notch ligand Jagged-1 and the 
Notch-responsive genes Hey1 and Hey2 was observed. 
Suppression of the Notch pathway inhibited IL-6 
expression and herceptin-resistance. Likewise, inhibiting 
Stat-3 signaling eliminated IL-6-induced Jagged-1 
expression and herceptin-resistance [121]. 
miR-34a targets Notch1 in MCF-7 breast cancer 
cells. Inhibition of Notch1 by miR-34a suppressed 
proliferation, migration, invasion and breast CSC 
propagation. Overexpression of miR-34a increased the 
sensitivity of breast cancer cells to paclitaxel. This was 
demonstrated to occur by suppression of the Notch1 
pathway. Overexpression of miR-34A also reduced 
mammosphere formation and ALDH1 in the presence 
of paclitaxel [122]. Figure 15 presents a diagram 
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documenting the effects of miR-34 and Notch on EMT.
miR-134 inhibits proliferation of human endometrial 
CSCs (HuECSCs). In contrast, the expression of miR-
134 was different in human endometrial cancer cells 
(HuECCS). miR-134 targeted protein O-glucosyltranferase 
1 (POGLUT1). Overexpression of miR-134 decreased the 
expression of POGLUT1 and Notch pathway members in 
HuECSCs and suppressed xenograft formation [123]. 
miR-34a has been shown to be a cell-fate 
determinant in colon CSCs. The levels of miR-
34a influence the balance between self-renewal and 
differentiation of colon CSCs. miR-34a sequestered 
Notch1 mRNAs [124]. 
miR34c expression was determined to be reduced in 
breast tumor initiating cells (BT-ICs) prepared from MCF-
7 and SK-3rd breast cancer cells. SK-3rd is a breast cell 
line which is enriched with BT-ICs. Elevated expression 
of miR-34c was determined to inhibit the self-renewal 
and EMT. This occurred by decreasing Notch4 expression 
[125]. 
TP53 regulates the expression of miR-34. 
Expression of miR-34a may be decreased in pancreatic 
cancer by epigenetic mechanisms as its expression was 
restored by 5-Aza-dC and SAHA (suberanilohydroxamic 
acid). These treatments inhibited cell proliferation, self-
renewal, EMT and invasion of pancreatic CSCs. In 
addition, these treatments inhibited expression of BCL-
2, cyclin-dependent kinase 6 (CDK6) and SIRT1 that 
are putative targets of miR-34a. The upregulation of 
miR-34a by these drugs resulted in acetylated TP53 in 
the pancreatic CSCs as well as the TP53 target genes: 
p21Cip-1, p27Kip-1 and PUMA. When miR-34a was inhibited 
by the antagomiR, the effects of 5-Aza-dC and SAHA 
were suppressed. The Notch pathway was inhibited in the 
pancreatic CSCs by SAHA.SAHA is a histone deacetylase 
(HDAC) inhibitor. SAHA treatment also resulted in 
inhibition of EMT and increased E-cadherin and decreased 
N-cadherin expression. Inducers of EMT such as: Zeb-
1, Snail and Slug were inhibited by SAHA treatment. 
Both 5-Aza-dC and SAHA suppressed pancreatic CSC 
migration and invasion [126]. 
Overexpression of Notch-1 in the ASPC-1 
pancreatic cancer cell line has been shown to increase cell 
growth, clonogenicity and invasion and lead to EMT by 
stimulation of the mesenchymal markers such as ZEB1, 
CD44, EpCAM and HES1. Notch-1 was also shown to 
influence miR expression. Notch expression resulted in 
increased levels of miR-21 and decreased levels of miR-
200b, miR-200c, let-7a, let-7b and let-7c. miR-200b re-
expression resulted in decreased expression of Zeb1 and 
vimentin but increased the levels of E-cadherin. Notch-1 
overexpression augmented pancreatospere formation 
and the expression of the CSC markers including CD44 
and EpCAM. Genistein treatment was determined to 
suppress cell growth, clonogenicity, migration, invasion, 
EMT, formation of pancreatospheres and expression of 
CD44 and EpCAM. The authors concluded that Notch-1 
signaling is important in the EMT phenotype, development 
of pancreatospheres and CD44 and EpCAM expression. 
Some of the effects are mediated by miR-200b [127]. 
The c-Met, Notch-1 and Notch-2 genes have been 
determined to be direct targets of miR-34a in gliomas. 
In glioma patient samples, c-Met levels were determined 
to be inversely correlated with miR-34 levels. c-Met and 
Notch were observed to be a least partially responsible 
for the inhibitory effects that miR-34a had on gliomas. 
Moreover, miR-34a expression could inhibit xenograft 
formation. miR-34a was also shown to induce glioma stem 
cell differentiation. [128]. 
miR-34 has been shown to regulate Notch and 
Bcl-2 in pancreatic CSCs. The MIA-PaCa2 and BxPC3 
pancreatic cancer cell lines contain mutant TP53 genes. 
When miR-34 expression was restored in these cells, 
downregulation of Bcl-2 and Notch1/2 occurred as 
well as decreased clonogenic cell growth, invasion, 
increased apoptosis, G1 and G2/M arrest, and sensitivity 
to chemotherapy and radiotherapy. CD44+/CD133+ 
MiaPaCa2 cells with down-regulated miR-34 were 
enriched with tumorsphere-forming and tumor initiating 
cells. In contrast, in those cells with miR-34 expression 
restored, the tumorsphere formation and tumor formation 
were significantly reduced [129]. 
miR-199b-5p has been shown to target the 
transcription of HES1 in medulloblastoma cells. HES1 
lies downsteam in the Notch pathway. miR-199-5p 
was shown to regulate negatively the proliferation and 
anchorage-independent growth of meduloblastoma cells. 
Overexpression of miR-199b-5p was also shown to block 
the expression of many genes that are involved in cancer 
stem cells. miR-199b-5p expression was examined in 
61 meduloblastoma patients. miR-199b-5b expression 
was significantly higher in the non-metastatic than in the 
metastatic patients. In addition, the patients with high 
miR-199b expression had a better overall survival. miR-
199b expression in metastatic meduloblastoma may be 
suppressed by epigenetic or genetic alterations [130]. 
miR-34 has also been shown to be important in 
gastric cancer tumorspheres. Kato III gastric cancer cells 
are mutant at TP53. Restoration of miR-34 was shown to 
reduce the expression of Bcl-2, Notch and high-mobility 
group AT-hook 2 (HMGA2), chemosensitized the cells and 
inhibited tumorsphere formation [131]. 
SUMMARY
GSK-3 is an important enzyme involved in 
numerous biochemical processes. The activity of GSK-3 
is regulated by numerous kinases and phosphatases. GSK-
3 can in turn regulate the activity of numerous substrates. 
GSK-3 activity can be dysregulated by various signal 
transduction pathways that are themselves aberrantly 
regulated in cancer often due to genetic and epigenetic 
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mechanisms. Often the substrates of GSK-3 are proteins 
involved in EMT and CSCs.
Recently, we have summarized the possibility of 
using various GSK-3 and Wnt-beta catenin inhibitors 
to treat cancer patients [4]. GSK-3 inhibitors may show 
potent effects on certain types of solid tumors. However, 
since GSK-3 can also function as a tumor suppressor, 
there has always been concern that inhibition of GSK-
3 could serve to stimulate the growth of certain tumors. 
This does not appear to be the case with at least certain 
types of cancer, as lithium has been used to treat maniac 
depression/bipolar disorder patients for a long time and 
increased cancer incidences to not appear to be present 
in these individuals. A recent search of clinicaltrial.gov 
does not reveal any current studies with GSK-3 inhibitors 
and cancer, although GSK-3 inhibitors are being clinically 
investigated in neurological diseases. Although, there have 
been some patients filed for the use of GSK-3 inhibitors in 
certain types of cancer patients.
miRs can also serve to regulate the expression 
of many genes involved in EMT. Many different genes 
have been implicated to be important in EMT and cancer. 
Recently, the histone genes have been shown to be 
important in EMT in uterine and ovarian carcinosarcomas 
[132]. The interactions between GSK-3, PI3K/PTEN/Akt/
mTORC1, Ras/Raf/MEK/ERK, Wnt/beta-catenin, Hh, 
Notch and TP53 pathways are clearly having important 
roles in regulating EMT and CSCs and some of the 
components may serve as prognostic indicators for various 
cancer. 
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